FDA
EMA
MHRA
PMDA
Health Canada

Clinical

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Competitive

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Markets

Pricing
Access
Commercial
Launch Tracking

M&A Watch

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

Intelligence powered by the Humanexa engine.

Asset / Drug

guselkumab

Drug and asset intelligence for guselkumab with 4 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 2
Catalysts: 2
Stage: Development stage unavailable

Sponsor company

AbbVie →

Recent signals(2)

CompetitiveAugust 9, 2026

JNJ-78934804 Shows Efficacy in Crohn's Disease Compared to Guselkumab

A study is underway to evaluate the efficacy and safety of JNJ-78934804 against guselkumab in Crohn's disease patients at Week 48.

ClinicalAugust 3, 2026

Study on Guselkumab Therapy's Impact on NAFLD in PsA Patients

The study investigates the effects of Guselkumab on disease severity in PsA patients with NAFLD.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts(2)

Topline Data

— Guselkumab

July 7, 2026 · N/A

Topline Data

— guselkumab

June 26, 2026 · N/A

Indications

Crohn's Disease →

Therapeutic areas

Crohn's Disease →

Dermatology · Psoriasis →

Gastroenterology →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.